Interim national advice supports a conditional puberty blocker option, but restrictions remain
The National Health and Medical Research Council released interim advice on 16 November recommending that puberty blockers remain a clinical option for some trans and gender-diverse young people. The recommendation is conditional, not an instruction that all young people should receive medication.
Treatment could be considered for a young person who has begun puberty, has gender incongruence with or without associated distress, and is assessed as suitable. Decisions should involve the young person, carers and clinicians, recognising that individual needs and choices differ.
The medicines, called gonadotropin-releasing hormone analogues or GnRHa, suppress sex hormones and pause aspects of physical development. Gender incongruence refers to a difference between gender and sex recorded at birth; associated distress is known as gender dysphoria.
The review included 15 non-randomised studies, mostly following participants for six months to two years. Overall certainty was low because research was mainly observational and short term. It found possible improvements in psychosocial functioning and reductions in suicidal behaviours, while serious adverse events appeared rare. No eligible evidence was found for outcomes including fertility, fractures and other bone-health measures. Such gaps do not establish that risks are absent.
The committee used the GRADE framework, which distinguishes the strength of a recommendation from certainty in the evidence. Conditional recommendations reflect uncertainty and the need for shared decisions. Patients should be monitored for symptoms requiring additional investigation or treatment.
Queensland and the Northern Territory said their public-system restrictions would not change. Queensland has extended its pause on new access until 2031 while awaiting further research, including a UK trial. The national advice is not legally binding and does not automatically override state or territory policies. Health Minister Mark Butler urged governments to consider it carefully.
Queensland's separate review led by psychiatrist Ruth Vine found limited evidence, including possible short- to medium-term bone-health effects, while identifying potential benefits under proper oversight. Puberty blockers have also long been used for unusually early puberty, a different clinical setting.
Randomised trials raise ethical questions about withholding or delaying treatment in children, and the visible effects of the medicines make blinding difficult. Low certainty does not mean proof of no benefit, but it limits confidence in estimates of benefit and harm. The interim advice is open for public consultation, with broader national guidelines due in 2028. This is a report on guidance, not individual medical advice.